| Bid | 2.07 |
| Market Cap | 36.62M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.44 |
| PE Ratio (ttm) | -0.49 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.48 |
| Volume | 77,844 |
| Avg. Volume (20D) | 80,385 |
| Open | 2.10 |
| Previous Close | 2.16 |
| Day's Range | 2.05 - 2.28 |
| 52-Week Range | 1.97 - 3.57 |
| Beta | undefined |
About OCX
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support...
Analyst Forecast
According to 3 analyst ratings, the average rating for OCX stock is "Buy." The 12-month stock price forecast is $4.25, which is an increase of 95.40% from the latest price.
Next Earnings Release
Analysts project revenue of $250.00K, reflecting a -20.38% YoY shrinking and earnings per share of -0.44, making a -79.82% decrease YoY.
1 week ago · prismmediawire.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerIrvine, Calif., Jan. 8, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medica...
1 month ago · prismmediawire.com
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor MeetingsJanuary 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 – PRISM MediaWire – Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executiv...
1 month ago · prismmediawire.com
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyIRVINE, Calif., Dec. 04, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay.
2 months ago · prismmediawire.com
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025IRVINE, Calif., Nov.
3 months ago · prismmediawire.com
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los AngelesIRVINE, Calif., Oct. 16, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main E...